UNSPSC 51321709: Atorvastatin lactone

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H33FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7876IL7J2N, chemically known as (+)-atorvastatin lactone, but more generally known as atorvastatin lactone, which bears US NIH Compound Identifier 6483036. European Medicines Agency schedules atorvastatin lactone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05600MIG.

Most nations, for tariff purposes, schedule atorvastatin lactone under HS 29339990. SMILES: CC(C)C1C(C(C(N1CC[C@@H]2C[C@H](CC(=O)O2)O)C3CCC(CC3)F)C4CCCCC4)C(=O)NC5CCCCC5.

UNSPSC 51321709 Atorvastatin lactone, a Commodity code, encompasses pharmaceutical supply sourcing for state and local health systems, emergency services, and health benefit programs — specifically generic and branded medications supplied through established wholesaler networks or direct manufacturer relationships. State and local governments buy under this code to stock advanced life support medications, manage formulary compliance across multi-jurisdictional pharmacy benefit programs, and maintain emergency medical services inventories. Issuing bodies include municipal fire and rescue departments, state health and human services agencies administering Medicaid or employee health benefits, and multistate cooperative purchasing alliances aggregating demand across member jurisdictions. The City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the typical range — from single-jurisdiction emergency medical supply to statewide and interstate benefit program procurement.

Recent activity spans Florida, Texas, and Minnesota-Oregon cooperative territory. The City of Tampa's Purchasing Department issued IFB No. 26P00188 on April 24, 2026 (due April 8, 2026) for advanced life support medications including epinephrine, adenosine, and diltiazem in quantities ranging from 330 to 1,810 units, with an estimated contract value of $40,000 and a one-year base term plus two optional one-year renewals; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 (due March 26, 2026) to establish multistate contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and a two-year contract term. The Texas HHS Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and wholesaler channels, signaling exploratory procurement before a formal RFP.